Magistro G, Marcon J, Eismann L, Volz Y, Stief C G
Urologische Klinik und Poliklinik, Klinikum der Universität München, Ludwig-Maximilians-Universität, Marchioninistraße 15, 81377, München, Deutschland.
Urologe A. 2020 Dec;59(12):1463-1471. doi: 10.1007/s00120-020-01368-6.
With the advent of novel high throughput-sequencing technologies we gained greater insights into the complex and diverse interactions of the microbiome for health and disease in the human body. The concept of urinary sterility has long been dismissed and now we strive for deciphering various microbial signatures associated with a disease. A dysbalance of the microbiome appears to have a substantial impact on the pathogenesis of both malignant and benign conditions. Novel preventive and therapeutic approaches and biomarker systems have been proposed for prostate cancer, renal cell carcinoma and bladder cancer based on microbiome analyses. The exclusion of a microbial origin was always part of the diagnosis of benign disorders such as interstitial cystitis, urinary urge incontinence or chronic prostatitis/chronic pelvic pain syndrome. Now we are certain that an imbalanced microbial profile plays an essential role for the pathogenesis and disease management of these challenging conditions.
随着新型高通量测序技术的出现,我们对微生物群在人体健康与疾病方面复杂多样的相互作用有了更深入的了解。长期以来,尿液无菌的概念已被摒弃,现在我们致力于破译与疾病相关的各种微生物特征。微生物群的失衡似乎对恶性和良性疾病的发病机制都有重大影响。基于微生物群分析,已经针对前列腺癌、肾细胞癌和膀胱癌提出了新的预防和治疗方法以及生物标志物系统。排除微生物起源一直是间质性膀胱炎、急迫性尿失禁或慢性前列腺炎/慢性盆腔疼痛综合征等良性疾病诊断的一部分。现在我们确定,微生物谱失衡在这些具有挑战性的疾病的发病机制和疾病管理中起着至关重要的作用。